Khreish, F.; Wiessner, M.; Rosar, F.; Ghazal, Z.; Sabet, A.; Maus, S.; Linxweiler, J.; Bartholomä, M.; Ezziddin, S.
Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy. Biomolecules 2021, 11, 1099.
https://doi.org/10.3390/biom11081099
AMA Style
Khreish F, Wiessner M, Rosar F, Ghazal Z, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S.
Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy. Biomolecules. 2021; 11(8):1099.
https://doi.org/10.3390/biom11081099
Chicago/Turabian Style
Khreish, Fadi, Mona Wiessner, Florian Rosar, Zaidoon Ghazal, Amir Sabet, Stephan Maus, Johannes Linxweiler, Mark Bartholomä, and Samer Ezziddin.
2021. "Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy" Biomolecules 11, no. 8: 1099.
https://doi.org/10.3390/biom11081099
APA Style
Khreish, F., Wiessner, M., Rosar, F., Ghazal, Z., Sabet, A., Maus, S., Linxweiler, J., Bartholomä, M., & Ezziddin, S.
(2021). Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy. Biomolecules, 11(8), 1099.
https://doi.org/10.3390/biom11081099
